Seagen Inc.: Seagen Announces Preliminary Results from Phase

- Frontline Treatment with ADCETRIS in Combination with Nivolumab, Doxorubicin and Dacarbazine (AN+AD) Shows a Complete Response Rate of 88%, Overall Response Rate of 93% and Favorable Safety Profile

Related Keywords

United States , Japan , California , Houston , Texas , Washington , Canada , Switzerland , Seattle , Canadian , American , David Caouette , Roger Dansey , Peggy Pinkston , Hun Ju Lee , National Cancer Institute , Md Anderson Cancer Center , Seagen Inc , Nasdaq , Exchange Commission , American Society Of Hematology , European Union , Corporate Communications , Department Of Lymphoma , Complete Response Rate , Overall Response Rate , Favorable Safety Profile , American Society , Annual Meeting , Associate Professor , Cancer Center , Chief Medical Officer , Safety Information , Boxed Warning , Lymphoma Response , Immunomodulatory Therapy Criteria , Prescribing Information , Quarterly Report , End Results , Vice President , Investor Relations , Seagen , Nnounces , Reliminary , Results , Rom , Hase , Linical , Trial , Adcetris , Rentuximab , Edotin , Novel , Combination , Agents , Patients , Dvanced , Stage , Classical , Hodgkin , Lymphoma ,